Latest Breaking News On - Josh rappaport - Page 2 : comparemela.com

Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024

Company to present an update of its ongoingmonotherapy and combinationPhase 1/1b study of WTX-124 in advanced or metastatic solid tumors

United statesJosh rappaportEllen lubmanCompany contactCompany or werewolf nasdaqScientific communicationsExchange commissionWerewolf therapeutics incAmerican society of clinical oncologyClinical oncologyAnnual meetingNon hodgkin lymphomaPrivate securities litigation reform act

ImPact Biotech to Present Interim Phase 3 Data from ENLIGHTED Study of Padeliporfin VTP in Low Grade UTUC at Upcoming Medical Conferences

ImPact Biotech to Present Interim Phase 3 Data from ENLIGHTED Study of Padeliporfin VTP in Low Grade UTUC at Upcoming Medical Conferences
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

San antonioUnited statesNatalia kudinovaMarc colombelRonaldp kaufman jrDina preiseRonald kaufmanJonathan colemanJonathan kesslerYaniv cohenAsaf shveroGautier marcqSteffen rauschDavidk imagawaAxelle mrozVitaly margulis

Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesJosh rappaportEllen lubmanExchange commissionWerewolf therapeutics incAmerican society of clinical oncologyScientific communicationsCompany contactCompany or werewolf nasdaqAbstract acceptedClinical oncologyAnnual meetingNon hodgkin lymphomaPrivate securities litigation reform act

Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting

Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesSan diegoEllen lubmanDanielj hicklinJosh rappaportCompany contactAmerican association for cancer researchExchange commissionWerewolf therapeutics incScientific communicationsCompany or werewolf nasdaqPro inflammatory cytokine therapeuticsAmerican associationCancer researchAnnual meetingChief executive officer

Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting

Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesDanielj hicklinJosh rappaportEllen lubmanCompany contactScientific communicationsCompany or werewolf nasdaqExchange commissionWerewolf therapeutics incAmerican association of immunologistsImmunology based diseasesWerewolf therapeuticsAmerican associationChief executive officerNon hodgkin lymphomaPrivate securities litigation reform act